← Leaderboards
Coleen A McNamara
University Of Virginia Charlottesville
$22,811,214
Attributed
$27,024,378
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,024,378 · 16
By mechanism
R01$18,731,923 · 9
P01$5,409,068 · 5
T32$2,883,387 · 2
Top collaborators
- Loren D Erickson9 shared
- Michael G Brown2 shared
- Shaoqin - Gong2 shared
- Lianwang Guo2 shared
- Anne I. Sperling2 shared
- K Craig Kent1 shared
- James C. Zimring1 shared
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Margaret A Shupnik$7,555,831
- Raghavendra G Mirmira$22,841,626
- Jerry L. Nadler$10,120,845
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMediatingAtherosclerosisMolecularMouse ModelDietImmuneAttenuatedLinkGenesBlood VesselsB-LymphocytesApolipoprotein ERegulationLeadInflammatoryProductionArterial Fatty StreakMacrophageCcr6 GeneLesionInflammationLipidsCohort
Grant awards (63)
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$1,002,379
R01 · FY2025 · AI
Targeted approach to the mitigation of abdominal aortic aneurysm$709,437
R01 · FY2025 · HL
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$522,656
R01 · FY2025 · AI
Interdisciplinary Training Program in Immunology$465,384
T32 · FY2025 · AI
G6PD Deficiency and Atherosclerosis$323,000
R01 · FY2025 · HL · contact PI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$802,379
R01 · FY2024 · AI
Targeted approach to the mitigation of abdominal aortic aneurysm$724,978
R01 · FY2024 · HL
Interdisciplinary Training Program in Immunology$437,025
T32 · FY2024 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$200,000
R01 · FY2024 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$802,379
R01 · FY2023 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$320,421
R01 · FY2023 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$286,590
R01 · FY2023 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$112,175
R01 · FY2023 · AI
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis$817,754
R01 · FY2022 · AI
Id3 and VSMC in Murine and Human Atherosclerosis$671,017
R01 · FY2022 · HL · contact PI
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis$403,750
R01 · FY2022 · HL · contact PI
Project 3: Regulation of atheroprotective IgM - producing B cells in murine and human atherosclerosis$43,069
P01 · FY2022 · HL · contact PI
Id3 and VSMC in Murine and Human Atherosclerosis$671,017
R01 · FY2021 · HL · contact PI
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis$403,750
R01 · FY2021 · HL · contact PI
B Cell Subsets in Mouse and Human Atherosclerosis$366,480
P01 · FY2021 · HL · contact PI
Local B-1 Regulation of Atherosclerosis$776,373
R01 · FY2020 · HL · contact PI
Id3 and VSMC in Murine and Human Atherosclerosis$671,017
R01 · FY2020 · HL · contact PI
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis$403,750
R01 · FY2020 · HL · contact PI
B Cell Subsets in Mouse and Human Atherosclerosis$366,021
P01 · FY2020 · HL · contact PI
Local B-1 Regulation of Atherosclerosis$780,851
R01 · FY2019 · HL · contact PI
Id3 and VSMC in Murine and Human Atherosclerosis$687,622
R01 · FY2019 · HL · contact PI
Somatic TET2 mutation-driven clonal hematopoiesis in atherosclerosis$403,750
R01 · FY2019 · HL · contact PI
B Cell Subsets in Mouse and Human Atherosclerosis$366,021
P01 · FY2019 · HL · contact PI
Local B-1 Regulation of Atherosclerosis$781,384
R01 · FY2018 · HL · contact PI
B Cell Subsets in Mouse and Human Atherosclerosis$365,953
P01 · FY2018 · HL · contact PI
Local B-1 Regulation of Atherosclerosis$783,960
R01 · FY2017 · HL · contact PI
B Cell Subsets in Mouse and Human Atherosclerosis$377,970
P01 · FY2017 · HL · contact PI
B- 1a Lymphoyctes in Atherosclerosis$434,341
P01 · FY2016 · HL · contact PI
B- 1a Lymphoyctes in Atherosclerosis$427,826
P01 · FY2015 · HL · contact PI
B- 1a Lymphoyctes in Atherosclerosis$425,653
P01 · FY2014 · HL · contact PI
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection$377,300
R01 · FY2014 · HL · contact PI
B- 1a Lymphoyctes in Atherosclerosis$413,493
P01 · FY2013 · HL · contact PI
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection$366,520
R01 · FY2013 · HL · contact PI
B- 1a Lymphoyctes in Atherosclerosis$452,841
P01 · FY2012 · HL · contact PI
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection$385,000
R01 · FY2012 · HL · contact PI
Genetic Regulation of B Lymphocyte Aortic Homing and Atheroprotection$385,000
R01 · FY2011 · HL · contact PI
Id3/B Lymphocytes and Atherosclerosis$498,195
R01 · FY2010 · HL · contact PI
Molecular mechanisms of enhanced vascular smooth muscle cell growth in diabetes$254,722
P01 · FY2010 · HL · contact PI
Id3/B Lymphocytes and Atherosclerosis$511,695
R01 · FY2009 · HL · contact PI
Molecular mechanisms of enhanced vascular smooth muscle cell growth in diabetes$276,358
P01 · FY2009 · HL · contact PI
Vascular Biology Research$207,736
T32 · FY2009 · HL · contact PI
Vascular Biology Research$376,251
T32 · FY2008 · HL · contact PI
Id3 Regulation of Smooth Muscle Cell Proliferation$325,345
R01 · FY2008 · HL · contact PI
Molecular mechanisms of enhanced vascular smooth muscle cell growth in diabetes$262,942
P01 · FY2008 · HL · contact PI
Vascular Biology Research$375,642
T32 · FY2007 · HL · contact PI
Id3 Regulation of Smooth Muscle Cell Proliferation$325,345
R01 · FY2007 · HL · contact PI
Molecular mechanisms of enhanced vascular smooth muscle cell growth in diabetes$314,919
P01 · FY2007 · HL · contact PI
Vascular Biology Research$384,209
T32 · FY2006 · HL · contact PI
Id3 Regulation of Smooth Muscle Cell Proliferation$335,062
R01 · FY2006 · HL · contact PI
Molecular mechanisms of enhanced vascular smooth muscle$260,459
P01 · FY2006 · HL · contact PI
Vascular Biology Research$371,275
T32 · FY2005 · HL
Id3 Regulation of Smooth Muscle Cell Proliferation$342,938
R01 · FY2005 · HL
HIGH BLOOD PRESSURE RESEARCH$265,865
T32 · FY2003 · HL
ID3 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION$280,467
R01 · FY2002 · HL
Mechanisms of enhanced vascular SMC growth in diabetes$0
P01 · FY2002 · HL
ID3 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION$272,299
R01 · FY2001 · HL
Mechanisms of enhanced vascular SMC growth in diabetes$0
P01 · FY2001 · HL
ID3 REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION$264,368
R01 · FY2000 · HL